The first patient has been dosed in a Phase 2B clinical trial evaluating the safety, efficacy, and tolerability of SAR442168 in people with relapsing multiple sclerosis(MS). SAR442168, formerly known as PRN2246, is being developed by Principia Biopharma, in...
Beta Bionics and Zealand Pharma initiate home-use trial of the iLet™ bionic pancreas with dasiglucagon for autonomous bihormonal treatment of Type 1 diabetes First home-use trial of the bihormonal iLet Bionic Pancreas System with dasiglucagon in a pre-filled,...
– IMVT-1401, a fully human anti-FcRn antibody administered via subcutaneous injection, is the only anti-FcRn antibody known to be in clinical development for the treatment of GO – Immunovant plans to initiate ASCEND-GO 2, a separate Phase 2b dose-ranging...
Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement and cognitive disorders, today announced the receipt of the second milestone payment from Novartis following the initiation of a Phase 2 clinical...
Gamma-sarcoglycanopathy (LGMD2C) is one of the most common limb-girdle myopathies. It affects less than 10 people per 1,000,000 and is characterized by progressive muscle weakness in the pelvis (pelvic girdle) and shoulders (scapular girdle), linked to mutations in...
Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA. For more information on DDW 2019, please refer...
Email
Text